Guyasuta Investment Advisors Inc. Acquires Shares of 6,740 Guardant Health, Inc. (NASDAQ:GH)

Guyasuta Investment Advisors Inc. purchased a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 6,740 shares of the company's stock, valued at approximately $206,000.

Several other hedge funds also recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock worth $232,325,000 after buying an additional 6,618,785 shares during the period. Eventide Asset Management LLC lifted its stake in shares of Guardant Health by 2.0% in the 3rd quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company's stock valued at $88,028,000 after purchasing an additional 76,762 shares during the period. Geode Capital Management LLC lifted its stake in shares of Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock valued at $64,754,000 after purchasing an additional 29,686 shares during the period. ARK Investment Management LLC lifted its stake in shares of Guardant Health by 233.5% in the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock valued at $34,701,000 after purchasing an additional 1,059,104 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Guardant Health by 19.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 238,037 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at $93,660. The trade was a 46.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 2,652 shares of company stock worth $93,192 in the last 90 days. Insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Guggenheim reaffirmed a "buy" rating on shares of Guardant Health in a research report on Wednesday, January 22nd. Barclays initiated coverage on Guardant Health in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 target price for the company. The Goldman Sachs Group boosted their target price on Guardant Health from $36.00 to $49.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Finally, Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday, October 30th. Sixteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $42.63.

Guardant Health Price Performance

Shares of NASDAQ GH traded up $0.73 during midday trading on Wednesday, reaching $49.00. The company's stock had a trading volume of 2,311,428 shares, compared to its average volume of 2,450,334. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89. The firm has a 50 day moving average price of $39.51 and a 200-day moving average price of $31.27. The stock has a market capitalization of $6.05 billion, a P/E ratio of -11.56 and a beta of 1.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.